Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Oral Communications

Tue, Nov 17, 2026 · 3:15–4:15 PM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC15 Treatment with Pepinemab, Anti-SEMA4D Blocking Antibody, Reduces a Unique Astrocyte Subset (Ast10) Correlated with Cognitive Decline and Associated Biomarkers of Synaptic Loss in People with Early-Stage AD; OC16 Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer's Disease; OC17 Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts; OC18 Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study.

Speakers